“EarlySight was born with a vision – to radically improve patient care by giving doctors the tool for earlier detection and better monitoring of retinal diseases.
With the unique ability to observe the retina down to the cellular level, EarlySight technology is at the forefront of imaging devices. The development of its AI-driven digital biomarker software will enable the company to offer a complete solution for eye doctors. It is the right time to answer the need for precision medicine.
I am proud to lead the EarlySight journey with the commitment of our collaborators, support from our investors, and the trust of our partners.”